XiuZheng
修正
Founded in 1995, the group owns well-known products such as “Stadashu,” “Xiuzheng” Hemorrhoid Suppositories, “Weidaning” Spray, and “Yiqi Yangxue” Oral Liquid. It is a large modern private pharmaceutical company integrating research, production, marketing of concentrated Chinese patent medicines, chemical pharmaceuticals, and biopharmaceuticals, as well as pharmaceutical retail chain operations and standardized cultivation of traditional Chinese medicinal materials. It engages in diversified development, including the health industry, tourism, and real estate, while focusing on its core pharmaceutical business. It operates both nationally and internationally, striving to develop the global market.
Founded by Chairman Xiu Laigui in May 1995, Xiuzheng Group is a large modern private pharmaceutical company that integrates research, production, marketing of concentrated Chinese patent medicines, chemical pharmaceuticals, and biopharmaceuticals. It also operates pharmaceutical retail chains and engages in the standardized cultivation of traditional Chinese medicinal materials. While emphasizing its pharmaceutical core, the company has also expanded into the health industry, tourism, and real estate sectors, pursuing diversified development. It operates both domestically and globally, exploring international markets.
By the end of 2016, the group had 127 subsidiary companies and employed over 100,000 people. It had developed 24 dosage forms and had over 2,000 varieties of medical and health products. Through secondary development, it cultivated several major products, including “Feining,” “Xiaomi Suppository,” “Six-Ingredient Rehmannia Pill,” “Neck and Waist Health,” and “Yiqi Yangxue.” The application of new formulation technologies led to the development of “Stadashu Microgranules” and “Dispersible Tablets,” ensuring Xiuzheng’s position in the domestic stomach medicine market. The company has established an integrated domestic research system comprising technology management, innovative drug research, and technology transfer. It has over 300 technical experts and holds more than 700 authorized patents. It has been recognized as a National Enterprise Technology Center, National Engineering Laboratory for Quality Control of Traditional Chinese Medicine, Postdoctoral Research Workstation, and Key Laboratory for Standardization of Traditional Chinese Medicine. The group’s Science and Innovation Center includes six research institutes, including the Beijing Xiuzheng New Drug Research Institute, Xiuzheng Biopharmaceutical (Hangzhou) Research Institute, and Beijing Medicinal Diet Research Institute. The group invests approximately 1 billion yuan in research funding annually. It is preparing to produce and market a Class 1 biopharmaceutical new drug, a recombinant urate oxidase injection for the treatment of tumor lysis syndrome. This makes it the second company in the world, after Sanofi, to produce this product.
The group has launched an international collaborative development platform for genetically recombined hypoglycemic drugs. It is jointly developing a series of hypoglycemic genetically engineered drugs, such as “Mendong Insulin” and “Dite Insulin,” with India. It is also implementing large-scale technology development for the industrialization of medicinal fungi.
Aiming to build a century-old Xiuzheng and establish a national brand, Xiuzheng Pharmaceutical aims to achieve a sales revenue target of 100 billion yuan within 10 years and reach a target of one trillion yuan by 2030. The company aspires to become one of the top 100 pharmaceutical companies globally.
Best-selling Products from the XIUZHENG Brand：
